Survival probabilities at 5 and 10 years in patients alive ≥2 years post-HCT, with corresponding SMRs, by NMD
| Primary disease . | n (%) . | 5 y (95% CI) . | 10 y (95% CI) . | SMR (95% CI) . | P . |
|---|---|---|---|---|---|
| Patients alive ≥2 y post-HCT | n = 4214 | 97 (96-97) | 93 (92-94) | 4.2 (3.7-4.8) | <.0001 |
| Bone marrow failure disorder | |||||
| SAA | 192 (5) | 98 (97-99) | 95 (93-97) | 1.8 (1.3-2.4) | .0009 |
| FA | 393 (9) | 96 (94-98) | 92 (88-95) | 4.8 (3.4-6.6) | <.0001 |
| Other marrow failure | 242 (6) | 95 (91-97) | 93 (88-96) | 6.4 (3.8-10) | <.0001 |
| Hemoglobinopathy | |||||
| Thalassemia | 401 (10) | 98 (97-99) | 98 (97-99) | 0.7 (0.3-1.4) | .3942 |
| SCD | 247 (6) | 97 (94-99) | 96 (93-98) | 8.3 (3.9-15) | <.0001 |
| Immunodeficiency syndrome | |||||
| SCID | 403 (10) | 97 (95-98) | 93 (90-96) | 4.8 (3.0-7.3) | <.0001 |
| Non-SCID PID | 607 (14) | 97 (96-99) | 95 (93-97) | 5.0 (3.3-7.4) | <.0001 |
| Histiocytic disorder | 273 (6) | 98 (96-99) | 94 (89-97) | 9.3 (4.8-16) | <.0001 |
| Inborn error of metabolism, leukodystrophy, other | |||||
| Metabolic disorder | 314 (7) | 93 (89-95) | 86 (81-90) | 25 (18-5) | <.0001 |
| Leukodystrophy | 143 (3) | 89 (83-94) | 75 (64-84) | 37 (37-53) | <.0001 |
| Osteopetrosis | 77 (2) | 93 (86-98) | 85 (74-93) | 11.5 (5.5-21) | <.0001 |
| Autoimmune disease | 12 (<1) | 100 | 83 (46-100) | 12.9 (0.3-72) | .1498 |
| Primary disease . | n (%) . | 5 y (95% CI) . | 10 y (95% CI) . | SMR (95% CI) . | P . |
|---|---|---|---|---|---|
| Patients alive ≥2 y post-HCT | n = 4214 | 97 (96-97) | 93 (92-94) | 4.2 (3.7-4.8) | <.0001 |
| Bone marrow failure disorder | |||||
| SAA | 192 (5) | 98 (97-99) | 95 (93-97) | 1.8 (1.3-2.4) | .0009 |
| FA | 393 (9) | 96 (94-98) | 92 (88-95) | 4.8 (3.4-6.6) | <.0001 |
| Other marrow failure | 242 (6) | 95 (91-97) | 93 (88-96) | 6.4 (3.8-10) | <.0001 |
| Hemoglobinopathy | |||||
| Thalassemia | 401 (10) | 98 (97-99) | 98 (97-99) | 0.7 (0.3-1.4) | .3942 |
| SCD | 247 (6) | 97 (94-99) | 96 (93-98) | 8.3 (3.9-15) | <.0001 |
| Immunodeficiency syndrome | |||||
| SCID | 403 (10) | 97 (95-98) | 93 (90-96) | 4.8 (3.0-7.3) | <.0001 |
| Non-SCID PID | 607 (14) | 97 (96-99) | 95 (93-97) | 5.0 (3.3-7.4) | <.0001 |
| Histiocytic disorder | 273 (6) | 98 (96-99) | 94 (89-97) | 9.3 (4.8-16) | <.0001 |
| Inborn error of metabolism, leukodystrophy, other | |||||
| Metabolic disorder | 314 (7) | 93 (89-95) | 86 (81-90) | 25 (18-5) | <.0001 |
| Leukodystrophy | 143 (3) | 89 (83-94) | 75 (64-84) | 37 (37-53) | <.0001 |
| Osteopetrosis | 77 (2) | 93 (86-98) | 85 (74-93) | 11.5 (5.5-21) | <.0001 |
| Autoimmune disease | 12 (<1) | 100 | 83 (46-100) | 12.9 (0.3-72) | .1498 |